Volume 147, Issue 1, Pages (October 2017)

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.

Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine.

Volume 144, Issue 1, Pages (January 2017)

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 150, Issue 3, Pages (September 2018)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Pain in cancer survivors; filling in the gaps

Volume 151, Issue 1, Pages (October 2018)

Volume 145, Issue 2, Pages (May 2017)

Volume 138, Issue 1, Pages (July 2015)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 144, Issue 2, Pages (February 2017)

Volume 147, Issue 1, Pages 3-10 (October 2017)

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Volume 141, Issue 2, Pages (May 2016)

Volume 135, Issue 1, Pages (October 2014)

Isaac M. Bromberg, MD Journal of Pain and Symptom Management

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 151, Issue 1, Pages (October 2018)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 136, Issue 2, Pages (February 2015)

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 145, Issue 2, Pages (May 2017)

Volume 148, Issue 1, Pages (January 2018)

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 146, Issue 1, Pages (July 2017)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

Volume 151, Issue 1, Pages (October 2018)

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 150, Issue 1, Pages (July 2018)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Volume 4, Issue 5, Pages 2-3 (October 2006)

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 147, Issue 3, Pages (December 2017)

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 3, Pages (September 2013)

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Evaluation of diagnostic tests

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 3, Pages (December 2017)

Physical Function in Patients with Cancer

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 154, Issue 1, Pages (July 2019)

Volume 115, Issue 1, Pages (October 2009)

Volume 154, Issue 2, Pages (August 2019)

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 147, Issue 1, Pages 139-144 (October 2017) Plasma and ovarian tissue sphingolipids profiling in patients with advanced ovarian cancer Paweł Knapp, Lubomir Bodnar, Agnieszka Błachnio-Zabielska, Magdalena Świderska, Adrian Chabowski Gynecologic Oncology Volume 147, Issue 1, Pages 139-144 (October 2017) DOI: 10.1016/j.ygyno.2017.07.143 Copyright © 2017 The Authors Terms and Conditions

Supplementary Fig 1 The ROC curves for concentration of sphingolipids in plasma patient with AOC: C16-Cer. The area under the ROC curve - 0.759 (a significantly higher risk AOC>311.88ng/100ml). Gynecologic Oncology 2017 147, 139-144DOI: (10.1016/j.ygyno.2017.07.143) Copyright © 2017 The Authors Terms and Conditions

Supplementary Fig 2 The ROC curves for concentration of sphingolipids in plasma patient with AOC: C18:1-Cer. The area under the ROC curve - 0.768 (a significantly higher risk AOC>4.75ng/100ml). Gynecologic Oncology 2017 147, 139-144DOI: (10.1016/j.ygyno.2017.07.143) Copyright © 2017 The Authors Terms and Conditions

Supplementary Fig 3 The ROC curves for concentration of sphingolipids in plasma patient with AOC: C18-Cer. The area under the ROC curve - 0.771 (a significantly higher risk AOC>100.76ng/100ml). Gynecologic Oncology 2017 147, 139-144DOI: (10.1016/j.ygyno.2017.07.143) Copyright © 2017 The Authors Terms and Conditions